Post-Aricept Patent Expiry, Eisai Starts Comeback With Roll-Out Of New Anti-Epileptic Fycompa In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Eisai hopes the launch of its first-in-class anti-epileptic drug Fycompa in Britain and other European markets will help offset revenues lost after its Aricept Alzheimer’s therapy went off patent in the region earlier this year, and signal a new phase of growth for the Japanese company.
You may also be interested in...
Eisai's Perampanel Phase III Outcomes Show Efficacy, But May Not Meet Company Hype
TOKYO - Eisai Co. Ltd. released generally positive results of a Phase III trial for epilepsy drug perampanel, a compound which the company has promoted heavily to investors and analysts, but discouraging results on dose-dependent efficacy may contribute to an underperformance of the hyped drug, according to a Tokyo pharma analyst
Eisai Plans R&D Revamp To Turn The Development Tide
Six autonomous product creation units to focus on neuroscience, oncology, antibodies and immunological anti-inflammatory diseases, with units also focused on late stage drugs and Japanese clinical research.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.